ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ALZN / options
ACXP (33) BGMS (38) SKYE (34) APRE (40) ⌘ Pro Terminal →

Alzamend Neuro Inc. (ALZN) Options Positioning, Max Pain & Unusual Sweeps

$1.25 +3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.26

Alzamend Neuro Inc. (ALZN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALZN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.25 (+3.31% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1016 tracked Health Care issuers, ALZN ranks #656 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALZN compare to ACXP and BGMS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and BGMS (Bio Green Med Solution Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.0M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALZN?
▼

Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $24.5M in revenue (+95.0% YoY), -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.26 (+0.41%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE ALZN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALZN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ALZN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$1.35-3.7% Next Q
Q2 (-2Q)
39
Grade E$1.30-13.1% Next Q
Q3 (-1Q)
37
Grade E$1.13+10.6% Next Q
Current
34
Grade E$1.25-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALZN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALZN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.52) and Max Pain ($1.31) forces dealer call-delta covering toward $2.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALZN Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ALZN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ALZN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALZN)

  • ✓Walkthrough of ALZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ALZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.61%📐 HORIZONTAL RANGE
2026-11-03O $1.22H $1.25L $1.21C $1.25VOL 25.0K
RES: $2.18SUP: $1.05SMA50: $1.52SMA200: $1.46
$2.18$1.86$1.54$1.22$0.90RES $2.18SUP $1.05$1.252026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALZN Butterfly Map → + Track ALZN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +95.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ALZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALZN)

Health Care Rank #656 of 1016 ⚔️ ACXP vs ALZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALZN vs. ACXP, BGMS, SKYE, APRE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alzamend Neuro Inc. (ALZN) ranks #656 by composite RQD confidence (34/100, grade E) and #928 by equity capitalization ($5.8M). Within this direct 5-issuer industry benchmark cohort, ALZN leads on earnings valuation at N/A trailing P/E, while ALZN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ALZN at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALZN ACTIVE
Alzamend Neuro Inc.
E 34/100 — — -35.0% +3.31% $5.8M Benchmark Subject
ACXP
Acurx Pharmaceuticals Inc.
E 33/100 — — -35.0% +2.89% $5.8M /acxp-vs-alzn →
BGMS
Bio Green Med Solution Inc.
D- 38/100 — — -35.0% 0.00% $6.0M /bgms-vs-alzn →
SKYE
Skye Bioscience Inc.
E 34/100 — — -35.0% +3.13% $5.7M /skye-vs-alzn →
APRE
Aprea Therapeutics Inc.
D- 40/100 — — -35.0% +1.32% $6.1M /apre-vs-alzn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001677077 ↗

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Alzamend Neuro Inc. (ALZN) reported GAAP revenue of $24.5M (+95.0% vs. FY2024 revenue of $12.6M , and -11.8% cumulative change since FY2023) , GAAP net income of -$8.8M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-22.8% YoY). On the balance sheet, ALZN closed FY2025 with $4.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-30 $24.5M -$8.8M -$8.1M -$8.1M $4.0M —
FY2024 (FY) 2025-04-30 $12.6M -$4.5M -$6.6M -$6.6M $4.2M —
FY2023 (FY) 2024-04-30 $27.8M -$9.9M -$8.3M -$8.3M — —

3. ALZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.25 (+3.31% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1016 tracked Health Care issuers, ALZN ranks #656 in composite RQD confidence.

How does ALZN compare to ACXP and BGMS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and BGMS (Bio Green Med Solution Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.0M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALZN?

Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $24.5M in revenue (+95.0% YoY), -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALZN trading relative to its 50-day, 200-day, and 52-week technical levels?

ALZN last traded at $1.25 (+3.31% on volume of 37,066 shares), positioning the stock -17.76% below its 50-day simple moving average ($1.52) and -14.38% below its 200-day simple moving average ($1.46). Across its 52-week range of $0.84 to $2.61, ALZN sits at the 23.2% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).

Direct Sub-Reports: ALZN RQD Cockpit ALZN 12M Forecast ALZN Earnings & Move ALZN Dividends & DRIP ALZN Insiders & 13F ALZN Whale Options ALZN Profit Sankey ALZN News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

ALZN — Alzamend Neuro Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-04-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Alzamend Neuro Inc. (ALZN) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.25 (+3.31% 1D, market capitalization $5.8M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alzamend Neuro Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $0.0B. Products, customers, and revenue model are — Reported revenue is — across the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-04-30), Alzamend Neuro Inc. (ALZN) reported $24.5M in annual revenue (up from $12.6M in FY2024, +95.0% YoY) and -$8.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($27.8M revenue, -$9.9M net income) through FY2025, ALZN scaled operating cash flow to -$8.1M and free cash flow to -$8.1M, backed by $4.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.84 – $2.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations beyond the Beta of 1.0 are — Investors should watch for disclosures on suppliers, partners, and clinical or licensing dependencies, none of which appear in the source data.

  • Key Question #1: Can ALZN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $24.5M and free cash flow of -$8.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ALZN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ALZN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alzamend Neuro Inc. (ALZN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALZN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALZN Bull vs. Bear Conversation Board — What's Your Call at $1.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALZN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ALZN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.56 (+28.9%)
📌 Pinned Debate

A reported upgrade to Buy and a 52-week low of $0.84 that sits well below the current $1.22 price suggest recent momentum.

The street is overcomplicating Alzamend Neuro Inc. (ALZN). A reported upgrade to Buy and a 52-week low of $0.84 that sits well below the current $1.22 price suggest recent momentum.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.31.

VolSurface_Trader 🐂 BULL

Both sides have a point here — ALZN's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.99 (-18.2%)
Spot @ $1.21

Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1 out of 9 show the business consuming capital with a weak balance sh

Sitting on the sidelines or leaning short ALZN above $1.21. Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1 out of 9 show the business consuming capital with a weak balance sheet.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.61.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%